Brain-derived neurotrophic factor (BDNF) plays an essential role in nervous system formation and functioning, including metabolism. Present only in humans, the "Val66Met" polymorphism of the BDNF gene () is suggested to have a negative influence on the etiology of neurological diseases. However, this polymorphism has only been addressed, at the molecular level, in nonhuman models. Knowledge about Val66- and Met66-variant differences, to date, has been achieved at the protein level using either cell culture or animal models. Thus, the purpose of our study was to analyze the impact of the Val66Met polymorphism on expression in healthy humans and compare the allele-specific responses to metabolic stress. Muscle biopsies from 13 male recreational athletes (34 ± 9 years, 1.80 ± 0.08 m, 76.4 ± 10.5 kg) were obtained before and immediately following a VOmax test. Allele-specific BDNF mRNA concentrations were quantified by droplet digital PCR (ddPCR) in heterozygous and homozygous subjects. The results indicated that expression levels were influenced by the genotype according to the presence of the polymorphism. expression from the Met66-coding alleles, in heterozygotes, was 1.3-fold lower than that from the Val66-coding alleles. Total BDNF mRNA levels in these heterozygotes remained below the whole sample's mean. A partial dominance was detected for the Val66-coding variant on the Met66-coding's. expression levels decreased by an average of 1.8-fold following the VOmax test, independent of the individual's genotype. The results of this study indicate that metabolic stress downregulates expression but not plasma BDNF concentrations. No correlation between expression level and plasma BDNF concentrations was found.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131668 | PMC |
http://dx.doi.org/10.3389/fnmol.2021.638176 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!